Every Form 4 that CORE SCIENTIFIC INC RTS (CORZR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CORZR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CORZR filings page.
Core Scientific, Inc. (CORZ) reported that its Chief Legal and Administrative Officer, Todd M. Duchene, sold 10,000 shares of common stock on September 8, 2026 at a weighted average price of $18.6735 per share under a Rule 10b5-1 trading plan adopted on December 5, 2025, leaving him with 1,217,896 shares held directly. On September 9, 2026, he made a charitable donation of 95,000 Tranche 1 Warrants, each exercisable for one share of common stock at $6.81 per share until January 23, 2027, with 422,133 such warrants remaining. A separate transfer on September 10, 2026 moved 700,000 shares of common stock into a grantor retained annuity trust of which he is the sole trustee, which are now reported as held indirectly.
Core Scientific, Inc. (CORZ) officer Todd M. Duchene, Chief Legal and Administrative Officer, reported selling 10,000 shares of common stock on August 31, 2026 at a weighted average price of $16.23 per share under a Rule 10b5-1 trading plan. After this sale, he held 1,927,896 shares directly.
Core Scientific, Inc. (CORZ) reported that its Chief Legal and Administrative Officer, Todd M. Duchene, sold 10,000 shares of common stock on August 24, 2026 in an open-market transaction at a weighted average price of $17.4493 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. After this transaction, Duchene directly holds 1,937,896 shares of Core Scientific common stock.
The filing notes that the 10,000 shares were sold in multiple trades at prices ranging from $17.17 to $17.77 per share.
Core Scientific, Inc. (CORZ) director Elizabeth Crain purchased Core Scientific common stock in the open market. She bought 6,000 shares of common stock on 2026-08-20 at a weighted average price of $18.3324 per share, in multiple trades between $18.27 and $18.345. Following this transaction, she directly holds 71,348 shares of Core Scientific common stock.
Core Scientific, Inc./tx (CORZ) director Eric Stanton Weiss reported an open-market purchase of 7,000 shares of Common Stock on August 18, 2026, at a weighted average price of $19.194 per share. After this transaction, he directly holds 259,262 CORZ shares. The price reflects multiple trades between $18.785 and $19.595 per share.
Core Scientific, Inc. (CORZ) insider Todd M. Duchene, the Chief Legal and Administrative Officer, reported transactions in Common Stock on August 17, 2026. He sold 10,000 shares in an open-market or private transaction at a weighted average price of $20.0974 per share, with individual sale prices ranging from $19.74 to $20.42. In a separate transaction the same day, 11,205 shares of common stock were disposed of to satisfy withholding tax obligations upon the vesting of restricted stock units. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2025.
Core Scientific, Inc. officer Todd M. Duchene, Chief Legal and Administrative Officer, reported open-market sales of company common stock. On August 10, 2026, he sold 9,000 shares at a weighted average price of $19.8986 per share and 1,000 shares at a weighted average price of $20.6480 per share. The filing states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025, and that the prices reflect multiple trades within disclosed ranges.
Core Scientific, Inc. reported that Chief Legal and Administrative Officer Todd M. Duchene sold a total of 10,000 shares of common stock on August 3, 2026. The sales occurred in three open market or private transactions at weighted-average prices of $20.3903, $21.55 and $22.6166 per share. All trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, with individual sales taking place within price ranges of $19.99–$20.72, $21.03–$21.95 and $22.12–$22.95 per share.
Adams Mark reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that director Mark Adams received a grant of 27,594 restricted stock units of common stock on July 30, 2026. These RSUs vest in two equal installments on July 30, 2027 and July 30, 2028, contingent on his continued service, resulting in direct ownership of 27,594 units.
Core Scientific, Inc. (CORZ) Chief Legal and Administrative Officer Todd M. Duchene reported selling a total of 10,000 shares of common stock on July 27, 2026, in three transactions reported as open-market or private sales.
The sales comprised 8,300 shares at $20.7469, 1,600 shares at $21.8925, and 100 shares at $22.4900 per share. The 8,300‑ and 1,600‑share trades were executed at weighted average prices within ranges of $20.47–$21.42 and $21.47–$22.44, respectively. All transactions were effected under a Rule 10b5-1 trading plan adopted on December 5, 2025.
Core Scientific, Inc. reported that CEO Adam Taylor Sullivan had 15,584 shares of common stock withheld on 2026-07-16 to satisfy tax obligations upon the vesting of restricted stock units at $22.72 per share, leaving 4,436,426 shares held directly.
Core Scientific, Inc. reported that Chief Legal and Administrative Officer Todd M. Duchene had 4,325 shares of Common Stock withheld on July 16, 2026 to satisfy withholding tax obligations upon the vesting of restricted stock units, at $22.72 per share. After this tax-withholding disposition, he directly holds 2,009,101 Common Stock shares.
Todd M. Duchene, an officer of Core Scientific, Inc., reported two open-market sales totaling 10,000 shares of Common Stock on July 13, 2026, at weighted average prices of $22.4301 and $23.0100 per share.
The transactions were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on December 5, 2025.
Core Scientific, Inc. officer Todd M. Duchene reported an open-market sale of 10,000 shares of Common Stock on July 6, 2026 at a weighted average price of $22.6254 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre-scheduled rather than discretionary. Following this sale, Duchene directly holds 2,023,426 shares of Core Scientific common stock.
Core Scientific, Inc. Chief Executive Officer Adam Taylor Sullivan reported a routine tax-related share disposition. A total of 18,023 shares of common stock were withheld on June 30, 2026 to cover withholding tax obligations triggered by the vesting of restricted stock units. This was not an open-market sale, but an automatic tax-withholding event. Following the transaction, Sullivan directly owned 4,452,010 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported open-market sales of 10,000 shares of Common Stock on June 29, 2026 at weighted average prices of about $25.99, $27.42 and $27.95, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
On June 30, 2026, an additional 5,469 shares were disposed of to satisfy withholding tax obligations upon vesting of restricted stock units, a non-market transaction. After these actions, Duchene directly owned 2,033,426 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling a total of 10,000 shares of Common Stock in open-market transactions. The sales occurred on June 22, 2026 at weighted average prices of $29.11 and $29.88, based on multiple trades within stated price ranges.
The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were scheduled in advance. After the transactions, he continues to hold a substantial direct equity position in Core Scientific.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of common stock in open-market transactions. The sales occurred on June 15, 2026 in two trades at weighted average prices of $28.79 and $28.19 per share. According to the disclosure, these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the timing was scheduled in advance rather than a discretionary move.
Core Scientific, Inc. reported that officer Todd M. Duchene sold a total of 10,000 shares of common stock in the open market on June 8, 2026. The sales occurred in two blocks: 4,500 shares at a weighted average price of $27.1053 per share and 5,500 shares at a weighted average price of $26.6376 per share.
The filing notes that these transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on December 5, 2025, meaning the trades were pre-arranged rather than timed at the officer’s discretion.
Core Scientific, Inc. officer Todd M. Duchene reported selling a total of 10,000 shares of Common Stock on June 1, 2026 in open-market transactions. The sales were executed in three blocks at weighted average prices of $26.9285, $28.2666, and $28.7561 per share.
The filing notes these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Footnotes explain that each reported price is a weighted average for multiple individual trades within price ranges from $26.54 to $28.97.
Smith Stephen M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific director Stephen M. Smith received a grant of 18,961 shares of Common Stock in the form of restricted stock units. The RSUs were granted at no cash cost and will vest in two substantially equal installments on May 26, 2027 and May 26, 2028, contingent on his continued service.
Core Scientific, Inc. officer Todd M. Duchene reported an open-market sale of 10,000 shares of Common Stock on May 26, 2026 at a weighted average price of $26.254 per share. The transactions were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were pre-scheduled. After these sales, Duchene directly holds 2,088,895 shares, so the sale represents a relatively small portion of his overall position. The shares were sold in multiple trades at prices ranging from $25.81 to $26.75.
Nygaard James P Jr reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. executive vice president and chief financial officer James P. Nygaard Jr. reported receiving a grant of 120,074 shares of Common Stock in the form of restricted stock units as equity compensation.
According to the filing, one-third of these RSUs will vest on March 15, 2027, and the remaining two-thirds will vest in eight substantially equal quarterly installments after that date, as long as he continues providing service to the company on each vesting date. Following this award, he holds 1,043,056 shares of Common Stock directly.
DUCHENE TODD M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that officer Todd M. Duchene received an annual grant of 138,547 shares of common stock in the form of restricted stock units on May 20, 2026, at no purchase price. One-third of these RSUs will vest on March 15, 2027, with the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter, as long as he continues serving the company on each vesting date. Following this equity award, Duchene directly holds 2,098,895 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock on May 11, 2026 in open-market transactions. The sales occurred in two blocks at weighted average prices of $22.8162 and $23.3916 per share. The filing states the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily. After these sales, Duchene continues to hold a substantial direct equity position in the company, so the activity represents a small portion of his overall holdings.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of the company’s common stock in open-market transactions. The sales occurred on May 4, 2026, at weighted-average prices of $21.53 for 100 shares and $20.8499 for 9,900 shares.
After these transactions, Duchene directly holds 1,980,348 shares of Core Scientific common stock. The filing notes the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction. The sale, executed on April 27, 2026, was made at a weighted average price of $20.939 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following this sale, Duchene directly holds 1,990,348 shares of Core Scientific common stock.
Core Scientific officer Todd M. Duchene sold shares in a planned transaction. On April 20, 2026, he completed an open-market sale of 10,000 shares of Core Scientific common stock at a weighted average price of $19.7952 per share under a Rule 10b5-1 trading plan adopted on December 5, 2025.
The shares were sold in multiple trades at prices ranging from $19.53 to $20.08. After this sale, Duchene directly holds 2,000,348 shares of Core Scientific common stock, indicating he retains a substantial equity position in the company.
Core Scientific, Inc. executive Todd M. Duchene reported a tax-related share disposition linked to equity compensation. On this Form 4, 16,741 shares of common stock were withheld at $19.08 per share to satisfy withholding tax obligations when restricted stock units vested. After this non-market, tax-withholding disposition, Duchene directly holds 2,010,348 shares of common stock.
Core Scientific CEO Adam Taylor reported a routine tax-related share disposition. On the vesting of restricted stock units, 87,355 shares of Common Stock were withheld at $19.08 per share to cover withholding tax obligations.
After this non-market transaction, Taylor directly holds 4,470,033 shares of Core Scientific common stock. Because the shares were withheld for taxes rather than sold on the open market, this filing reflects compensation and tax mechanics more than a change in investment view.
Core Scientific, Inc. officer Todd M. Duchene reported open-market sales of 10,000 shares of Common Stock on April 13, 2026, in two transactions pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. The shares were sold at weighted average prices within ranges of $17.94–$18.90 and $18.97–$19.04 per share. Following these sales, Duchene directly holds 2,027,089 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $16.4865 per share. After this sale, he directly holds 2,037,089 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and the shares were sold in multiple transactions at prices ranging from $16.285 to $16.78.
Core Scientific, Inc. Chief Executive Officer Adam Taylor reported equity compensation activity involving performance-based restricted stock units (PSUs) and related tax withholding. On March 31, 2026, he acquired 741,545 shares of Common Stock at $0.00 per share upon vesting and settlement of previously granted PSUs tied to specified performance criteria.
On the same date, 315,307 shares of Common Stock were withheld at $14.96 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, a non–open-market, tax-related disposition. After these transactions, Taylor directly held 4,557,388 shares of Common Stock, reflecting routine compensation and tax-settlement mechanics rather than open-market buying or selling.
Core Scientific, Inc. officer Todd M. Duchene reported a mix of equity compensation and share dispositions. On March 31, he received 216,734 shares of common stock through the settlement of performance-based restricted stock units, while 97,652 shares were withheld to cover tax obligations upon vesting.
On April 1, Duchene sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $15.2523 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 2,047,089 shares of Core Scientific common stock.
Core Scientific EVP and CFO James P. Nygaard Jr. reported a tax-related share disposition. On March 17, 2026, 92,725 shares of Common Stock were withheld at $16.42 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, rather than sold in the open market.
After this withholding, Nygaard directly owns 928,928 shares of Core Scientific common stock. Footnotes indicate that a portion of his holdings also reflects earlier in-kind share distributions received for no cash consideration.
Core Scientific director Eric Stanton Weiss bought 7,000 shares of common stock in an open-market transaction at an average price of $14.5285 per share on March 9, 2026. After this purchase, he directly holds 252,262 shares of Core Scientific common stock.
Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.
The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.